📈 They focus on next-generation monolithic chromatography for gene and cell therapies.
🔬 BCI aims to enhance bioprocessing efficiency by addressing bottlenecks with innovative solutions.
🌏 Singapore is seen as a vital hub for biomanufacturing, supporting BCI’s growth and technology development.
Introduction:
BioChromatographix International (BCI) has officially launched its operations in Singapore. The company aims to innovate the field of bioprocessing through the development of next-generation monolithic chromatography media, targeting applications in gene therapy, cell therapy, and advanced biologics manufacturing.
- BCI’s mission is to enhance bioprocessing efficiency, scalability, and reliability through innovative chromatography solutions.
- The company’s chromatography media utilizes novel methacrylic materials and proprietary monolithic architectures to ensure consistency and cost-efficiency in biotherapeutics production.
- BCI addresses existing bottlenecks in bioprocessing by offering technologies built for future therapeutic needs.
- The flagship platform, AXISFLOW™, is designed to purify various materials, including AAV, lentivirus, plasmid DNA, and mRNA.
- Founders emphasize Singapore’s supportive biotech ecosystem, providing a gateway to Asia’s diverse markets while enhancing BCI’s global competitiveness.
Conclusion:
The launch of BioChromatographix International in Singapore signifies a strategic effort to evolve purification technologies in response to the growing demands of modern biomanufacturing. By leveraging advanced chromatography solutions, BCI aims to facilitate the production of novel therapeutics while ensuring that its technologies remain scalable and commercially viable.
